Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-002822-10 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine 45 mg BID in patients with early stage HD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pridopidine | Experimental | 45 mg pridopidine twice daily (BID) |
|
| Placebo | Placebo Comparator | Matching placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pridopidine | Drug | Pridopidine hard gelatin capsule |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT) | The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings [domestic chores, activities of daily living, finances, care level, and occupation]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity. | From baseline to Week 65 |
| Change From Baseline to Week 65 in the UHDRS TFC Score (ITT) | The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings [domestic chores, activities of daily living, finances, care level, and occupation]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity. | From baseline to Week 65. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT) | The composite Unified Huntington Disease Rating Scale (cUHDRS) uses 4 components: Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Higher score = worse outcome. Best score=0. Worst score= 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. Best score=100. Worst score=0. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to match numbers with symbols. Scores = correct answers in 90 sec. Higher score = better outcome. Best score=120. Worst score=0. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. Higher score = better outcome. Best score=13. Worst score=0. Total integrated cUHDRS scale range: -7.6 to 24.8. The higher, the better. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in cUHDRS Total Score - Patients Off ADMs (mITT) | The composite Unified Huntington Disease Rating Scale (cUHDRS) assesses 4 components (see secondary outcome for details): Total Motor Score (TMS) for motor features. Higher score = worse outcome. Worst = 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Higher score = better outcome. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Higher score = better outcome. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. The higher, the better. Total cUHDRS scale range: -7.6 to 24.8 (assuming 150 as the max score of SWR). The higher, the better. This sensitivity analysis was performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. |
INCLUSION CRITERIA MAIN STUDY
EXCLUSION CRITERIA
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yael Cohen | Prilenia | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prilenia Investigational Site (Site 061) | Davis | California | 95616 | United States | ||
| Prilenia Investigational Site (Site 051) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40913168 | Derived | Reilmann R, Feigin A, Rosser AE, Kostyk SK, Saft C, Cohen Y, Schuring H, Hand R, Tan AM, Chen K, Feng W, Navon-Perry L, Cruz-Herranz A, Syltevik C, Boot D, Squitieri F, Kayson E, Mehra M, Goldberg YP, Geva M, Hayden MR; PROOF-HD study investigators. Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial. Nat Med. 2025 Nov;31(11):3780-3789. doi: 10.1038/s41591-025-03920-3. Epub 2025 Sep 5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Pridopidine | 45 mg pridopidine twice daily (BID) Pridopidine: Pridopidine hard gelatin capsule |
| FG001 | Placebo | Matching placebo Placebo: Pridopidine-matching placebo hard gelatin capsule |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Nov 10, 2022 | Jun 13, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Pridopidine-matching placebo hard gelatin capsule |
|
| From baseline to Week 65 |
| Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78 |
| Change From Baseline in Q-Motor Finger Tapping Inter-Onset Interval (IOI) Mean - Patients Off ADMs (mITT) | Quantitative (Q)-motor is a clinical assessment of fine motor skills. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. The index finger is positioned above a force transducer and is to tap as fast as possible. The start was defined as a rise of the force by 0.05 Newton above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. The IOI refers to the time between the onset of consecutive taps (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Time course from baseline to Week 26, Week 52, Week 65, and Week 78. |
| Change From Baseline in Q-Motor Pronation/Supination Inter-Tap-Interval (ITI) Mean - Patients Off ADMs (mITT) | Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assesses the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is ITI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Time course from baseline to Week 26, Week 52, Week 65, and Week 78. |
| Change in Q-Motor Pronation/Supination Inter-Onset-Interval (IOI) Mean - Patients Off ADMs (mITT) | Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assess the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is IOI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Time course from baseline to Week 26, Week 52, Week 65, and Week 78. |
| Change From Baseline in the UHDRS TFC Score - Patients Off ADMs (mITT) | Total Functional Capacity (TFC) tests the capacity to maintain domestic chores, activities of daily living, finances, care level, and occupation. Scores from 0 - 13. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78 |
| Change From Baseline in Stroop Word Reading (SWR) - Patients Off ADMs (mITT) | Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78 |
| Change From Baseline in Symbol Digit Modalities Test (SDMT) - Patients Off ADMs (mITT) | Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to write match numbers with symbols. Scoring sums correct substitutions in 90 second interval (max = 110). Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78. |
| Change From Baseline in Total Motor Score (TMS) - Patients Off ADMs (mITT) | Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Each rated 0 (normal) - 4 (abnormal). Higher score = worse outcome. Worst = 124. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78. |
| San Diego |
| California |
| 92093 |
| United States |
| Prilenia Investigational Site (Site 343) | Englewood | Colorado | 80113 | United States |
| Prilenia Investigational Site (Site 333) | Washington D.C. | District of Columbia | 20057 | United States |
| Prilenia Investigational Site (Site 160) | Gainesville | Florida | 32611 | United States |
| Prilenia Investigational Site (Site 019) | Tampa | Florida | 33620 | United States |
| Prilenia Investigational Site (Site 032) | Atlanta | Georgia | 30322 | United States |
| Prilenia Investigational Site (Site 088) | Chicago | Illinois | 60611 | United States |
| Prilenia Investigational Site (Site 029) | Kansas City | Kansas | 66103 | United States |
| Prilenia Investigational Site (Site 083) | Wichita | Kansas | 67226 | United States |
| Prilenia Investigational Site (Site 087) | Louisville | Kentucky | 40292 | United States |
| Prilenia Investigational Site (Site 028) | Baltimore | Maryland | 21218 | United States |
| Prilenia Investigational Site (Site 017) | Boston | Massachusetts | 02114 | United States |
| Prilenia Investigational Site (Site 076) | Boston | Massachusetts | 02215 | United States |
| Prilenia Investigational Site (Site 027) | St Louis | Missouri | 63130 | United States |
| Prilenia Investigational Site (Site 037) | Albany | New York | 12208 | United States |
| Prilenia Investigational Site (Site 002) | New York | New York | 10027 | United States |
| Prilenia Investigational Site (Site 119) | Durham | North Carolina | 27708 | United States |
| Prilenia Investigational Site (Site 089) | Cincinnati | Ohio | 45221 | United States |
| Prilenia Investigational Site (Site 020) | Columbus | Ohio | 43210 | United States |
| Prilenia Investigational Site (Site 006) | Portland | Oregon | 97239 | United States |
| Prilenia Investigational Site (Site 018) | Philadelphia | Pennsylvania | 19104 | United States |
| Prilenia Investigational Site (Site 031) | Nashville | Tennessee | 37232 | United States |
| Prilenia Investigational Site (Site 199) | Houston | Texas | 77004 | United States |
| Prilenia Investigational Site (Site 326) | Richmond | Virginia | 23284 | United States |
| Prilenia Investigational Site (Site 096) | Seattle | Washington | 98195 | United States |
| Prilenia Investigational site (Site 291) | Innsbruck | Austria |
| Prilenia Investigational Site (Site 030) | Calgary | Alberta | AB T2N 1N4 | Canada |
| Prilenia Investigational Site (Site 048) | Vancouver | British Columbia | BC V6T 1Z4 | Canada |
| Prilenia Investigational Site (Site 098) | Montreal | Quebec | QC H2X 3E4 | Canada |
| Prilenia Investigational Site (Site 232) | Halifax | NS B3S 1L8 | Canada |
| Prilenia Investigational Site (Site 388) | Prague | Czechia |
| Prilenia Investigational Site (Site 385) | Lille | France |
| Prilenia Investigational Site (Site 384) | Marseille | France |
| Prilenia Investigational Site (Site 392) | Paris | France |
| Prilenia Investigational Site (Site 234) | Aachen | Germany |
| Prilenia Investigational Site (Site 379) | Bochum | Germany |
| Prilenia Investigational Site (Site 377) | Lübeck | Germany |
| Prilenia Investigational Site (Site 376) | Münster | Germany |
| Prilenia Investigational site (Site 292) | Taufkirchen | Germany |
| Prilenia Investigational Site (Site 175) | Ulm | Germany |
| Prilenia Investigational Site (Site 249) | Bari | Italy |
| Prilenia Investigational Site (Site 394) | Bologna | Italy |
| Prilenia Investigational Site (Site 239) | Milan | Italy |
| Prilenia Investigational Site (Site 393) | Naples | Italy |
| Prilenia Investigational Site (Site 228) | Roma | Italy |
| Prilenia Investigational Site (Site 044) | Leiden | Netherlands |
| Prilenia Investigational Site (Site 387) | Maastricht | Netherlands |
| Prilenia Investigational Site (Site 386) | Gdansk | Poland |
| Prilenia Investigational Site (Site 244) | Krakow | Poland |
| Prilenia Investigational Site (Site 246) | Warsaw | Poland |
| Prilenia Investigational Site (Site 380) | Barcelona | Spain |
| Prilenia Investigational Site (Site 381) | Burgos | Spain |
| Prilenia Investigational Site (Site 176) | Madrid | Spain |
| Prilenia Investigational Site (Site 382) | Valencia | Spain |
| Prilenia Investigational Site (Site 180) | Aberdeen | United Kingdom |
| Prilenia Investigational Site (Site 390) | Cardiff | United Kingdom |
| Prilenia Investigational Site (Site 378) | Newcastle | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Pridopidine | 45 mg pridopidine twice daily (BID) Pridopidine: Pridopidine hard gelatin capsule |
| BG001 | Placebo | Matching placebo Placebo: Pridopidine-matching placebo hard gelatin capsule |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||||
| HD stage at randomization | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT) | The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings [domestic chores, activities of daily living, finances, care level, and occupation]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity. | The modified intent to treat (mITT) population included all participants in the ITT population who received at least one dose of study drug and had valid in clinic TFC scores both at baseline and at least one post-baseline timepoint. The mITT population was analyzed according to the treatment to which the participant was randomized. The mITT population was the main analysis population for the primary endpoint in non-EMA regions. Note that the analysis was based on observed data. | Posted | Least Squares Mean | Standard Error | score on a scale | From baseline to Week 65 |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Change From Baseline to Week 65 in the UHDRS TFC Score (ITT) | The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings [domestic chores, activities of daily living, finances, care level, and occupation]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity. | The intent to treat (ITT) population included all randomized participants. The ITT population was analyzed according to the treatment to which the participant was randomized. The ITT population was the main analysis population for the primary endpoint in the EMA region. | Posted | Least Squares Mean | Standard Error | score on a scale | From baseline to Week 65. |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT) | The composite Unified Huntington Disease Rating Scale (cUHDRS) uses 4 components: Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Higher score = worse outcome. Best score=0. Worst score= 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. Best score=100. Worst score=0. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to match numbers with symbols. Scores = correct answers in 90 sec. Higher score = better outcome. Best score=120. Worst score=0. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. Higher score = better outcome. Best score=13. Worst score=0. Total integrated cUHDRS scale range: -7.6 to 24.8. The higher, the better. | The modified intent to treat (mITT) population included all participants in the ITT population who received at least one dose of study drug and had valid in-clinic TFC scores both at baseline and at least one post-baseline timepoint. The mITT population was analyzed according to the treatment to which the participant was randomized. Note that the analysis was based on as observed data only, patient numbers are therefore lower. | Posted | Least Squares Mean | Standard Error | score on a scale | From baseline to Week 65 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change From Baseline in cUHDRS Total Score - Patients Off ADMs (mITT) | The composite Unified Huntington Disease Rating Scale (cUHDRS) assesses 4 components (see secondary outcome for details): Total Motor Score (TMS) for motor features. Higher score = worse outcome. Worst = 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Higher score = better outcome. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Higher score = better outcome. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. The higher, the better. Total cUHDRS scale range: -7.6 to 24.8 (assuming 150 as the max score of SWR). The higher, the better. This sensitivity analysis was performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | The mITT population was used for subgroup analyses. Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | score on a scale | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change From Baseline in Q-Motor Finger Tapping Inter-Onset Interval (IOI) Mean - Patients Off ADMs (mITT) | Quantitative (Q)-motor is a clinical assessment of fine motor skills. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. The index finger is positioned above a force transducer and is to tap as fast as possible. The start was defined as a rise of the force by 0.05 Newton above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. The IOI refers to the time between the onset of consecutive taps (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | The mITT population was used for subgroup analyses. Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | milliseconds (decrease = improvement) | Time course from baseline to Week 26, Week 52, Week 65, and Week 78. |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change From Baseline in Q-Motor Pronation/Supination Inter-Tap-Interval (ITI) Mean - Patients Off ADMs (mITT) | Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assesses the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is ITI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | The mITT population was used for subgroup analyses. Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | milliseconds | Time course from baseline to Week 26, Week 52, Week 65, and Week 78. |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change in Q-Motor Pronation/Supination Inter-Onset-Interval (IOI) Mean - Patients Off ADMs (mITT) | Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assess the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is IOI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | The mITT population was used for subgroup analyses. Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | milliseconds | Time course from baseline to Week 26, Week 52, Week 65, and Week 78. |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change From Baseline in the UHDRS TFC Score - Patients Off ADMs (mITT) | Total Functional Capacity (TFC) tests the capacity to maintain domestic chores, activities of daily living, finances, care level, and occupation. Scores from 0 - 13. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | The mITT population was used for subgroup analyses. Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | score on a scale | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change From Baseline in Stroop Word Reading (SWR) - Patients Off ADMs (mITT) | Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | The mITT population was used for subgroup analyses. Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | score on a scale | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change From Baseline in Symbol Digit Modalities Test (SDMT) - Patients Off ADMs (mITT) | Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to write match numbers with symbols. Scoring sums correct substitutions in 90 second interval (max = 110). Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | score on a scale | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78. |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change From Baseline in Total Motor Score (TMS) - Patients Off ADMs (mITT) | Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Each rated 0 (normal) - 4 (abnormal). Higher score = worse outcome. Worst = 124. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study. | Note: Analyses/p-values were generated on observed data. Patient numbers at individual weeks varied. | Posted | Least Squares Mean | Standard Error | score on a scale | Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78. |
|
|
From Screening until 2 weeks after End of Study/End of Treatment visit (total treatment period of up to 78 weeks).
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Pridopidine | 45 mg pridopidine twice daily (BID) Pridopidine: Pridopidine hard gelatin capsule | 4 | 250 | 34 | 250 | 204 | 250 |
| EG001 | Placebo | Matching placebo Placebo: Pridopidine-matching placebo hard gelatin capsule | 1 | 249 | 21 | 249 | 212 | 249 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Suicidal ideation | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Suicide attempt | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Delusion | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Paranoia | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Psychotic disorder | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Anxiety disorder | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Irritability | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Accident | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Brain contusion | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Facial bones fracture | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Fibula fracture | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Head injury | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Limb injury | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Patella fracture | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Spinal cord injury cervical | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Subdural hematoma | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Tibia fracture | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| COVID-19 pneumonia | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Appendicitis perforated | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.0) | Non-systematic Assessment |
| |
| Meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.0) | Non-systematic Assessment |
| |
| Spinal cord neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.0) | Non-systematic Assessment |
| |
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.0) | Non-systematic Assessment |
| |
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.0) | Non-systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Gastrointestinal hemorrhage | Gastrointestinal disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Gastrointestinal polyp hemorrhage | Gastrointestinal disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Hematemesis | Gastrointestinal disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Ataxia | Nervous system disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Chorea | Nervous system disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Radiculopathy | Nervous system disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Acute myocardial infarction | Cardiac disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Aortic valve incompetence | Cardiac disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Death | General disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Gait disturbance | General disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Hyponatremia | Metabolism and nutrition disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Malnutrition | Metabolism and nutrition disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Microcytic anemia | Blood and lymphatic system disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Weight decreased | Investigations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Hematoma | Vascular disorders | MedDRA (23.0) | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Weight decreased | Investigations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Contusion | Injury, poisoning and procedural complications | MedDRA (23.0) | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (23.0) | Non-systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (23.0) | Non-systematic Assessment |
|
PIs are not employed by the organization sponsoring the study.
There is an agreement between PIs and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Data and results are owned by the sponsor. Results can be used by the institution for (a) internal noncommercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of the sponsor.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Prilenia | Prilenia | +972 775558 | info@prilenia.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Mar 28, 2023 | Jun 13, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D006816 | Huntington Disease |
| ID | Term |
|---|---|
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D003704 | Dementia |
| D002819 | Chorea |
| D020820 | Dyskinesias |
| D009069 | Movement Disorders |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C483720 | pridopidine |
Not provided
Not provided
Not provided
| >=65 years |
|
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Austria |
|
| Netherlands |
|
| United States |
|
| Czechia |
|
| Poland |
|
| Italy |
|
| United Kingdom |
|
| France |
|
| Germany |
|
| Spain |
|
| HD2 |
|
|
|
|
| OG001 | Placebo | Matching placebo Placebo: Pridopidine-matching placebo hard gelatin capsule |
|
|
|
|
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|